A phase Ib/IIa trial of intravenous AU-105 in pediatric and adult patients with newly diagnosed glioblastoma
Latest Information Update: 11 Jul 2016
Price :
$35 *
At a glance
- Drugs AU 105 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Aurora BioPharma
- 11 Jul 2016 Status changed from planning to completed, as per company's pipeline.
- 16 Mar 2016 New trial record